The US Environmental Protection Agency (EPA) plans to abandon landmark regulations limiting airborne mercury and greenhouse ...

The administration of US President Donald Trump has launched a full-fledged assault on science and public health;1 its “flood the zone” strategy created chaos and initially overwhelmed potential ...

Physicians treating patients with Crohn's disease face a plethora of drug choices. Yet, overall rates of clinical response seem stable over time,1 suggesting the existence of a therapeutic ceiling ...

Over the past decade, several novel immunotherapies have transformed the treatment landscape of relapsed or refractory B-cell acute lymphoblastic leukaemia. In the pivotal TOWER trial, blinatumomab—a ...

The field of cellular immunotherapy has undergone a profound transformation in recent years, with autologous chimeric antigen receptor (CAR) T-cell therapies emerging as the standard-of-care option ...

Negotiations are ongoing in New York to agree the latest UN political declaration on non-communicable diseases (NCDs) and ...

We have witnessed weight loss of 13–15% with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and up to 18–23% with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) ...

One small city's bid to rescue its health finances has transformed the way health care is managed across China. Chris McCall ...

Non-valvular atrial fibrillation accounts for 13–26% of acute ischaemic strokes.1 Direct oral anticoagulants (DOACs) are ...

On May 6, 2025, the Global Initiative For Asthma (GINA) published the 2025 update to their Global Strategy for Asthma ...

We welcome the Lancet Child & Adolescent Health Commission on the future of neonatology, calling for much needed attention to ...

Gilead's lenacapavir approval by the US Food and Drug Administration (FDA) marks a milestone in HIV prevention, but experts warn over its expense. Sophie Cousins reports.